Foundation Medicine pursues $150M secondary offering; Micro-lens maker Presbia files IPO plans;

@FierceMedDev: Is there such a thing as a 'gentle' colonoscopy device? Invendo thinks so--and brought in $28M for its new tool. Item | Follow @FierceMedDev

@MarkHFierce: Qiagen hit the Chinese market with its next-gen TB test. Competition looms. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. Story via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Cochlear scored FDA approval for its innovative hearing aid system. Story | Follow @EmilyWFierce

> Cancer diagnostic startup Foundation Medicine ($FMI), which just completed an IPO late last year, plans to raise up to $150 million more in a secondary offering. Story (sub. req).

> Presbia, maker of a micro-lens corneal implant, has filed plans for an IPO worth up to $90 million. Story

> Minnesota's OnPoint Medical Diagnostics filed for Chapter 11 bankruptcy protection and plans to sell its assets to Alliance HealthCare Services in California, a provider of diagnostic-imaging and radiation therapy services. The company had hoped to commercialize technology developed at the Mayo Clinic. Story

> The Netherlands' Bioneedle Technologies Group is developing a tiny biodegradable implant designed to deliver a vaccine and then dissolve as it does its job. Story

> Shanghai-based MicroPort won Chinese regulatory approval for a new, targeted drug-delivery stent for coronary disease. Story

Biotech News

@FierceBiotech: Versartis grabs $126M in an upsized IPO to fund its orphan drug. News | Follow @FierceBiotech

@JohnCFierce: Merck, Endocyte score crucial EMA OK for conditional approval of vintafolide. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Article | Follow @DamianFierce

@EmilyMFierce: Public-private Japanese partnership invests $15M in neglected diseases. Story | Follow @EmilyMFierce

> Partnerless Aveo is back on the hunt as Biogen returns a cancer drug. Piece

> Novo says Tresiba's down but not out of the blockbuster diabetes race. Read

Pharma News

@FiercePharma: Yesterday's top-read FiercePharmaManufacturing story: NVS CEO predicts generic industry fallout as quality takes center stage. More | Follow @FiercePharma

@TracyStaton: Contrary to popular belief, side-effect reports on new meds hit a steady pace, study finds. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. News | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Arkansas court boots $1.2B J&J verdict on technical grounds. Article | Follow @CarlyHFierce

> J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face. Story

> Wockhardt plants cited by Indian regulators. More

> Novo CEO sees improved picture for Tresiba in U.S. market. Piece

Editor's Note: A story on Invendo in Thursday's FierceMedicalDevices misstated the location of Garden City. It is in New York state.

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.